Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
Ticker SymbolCUPR
Company nameCuprina Holdings (Cayman) Ltd
IPO dateApr 10, 2025
CEOMr. Yong Qi (David) Quek
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 10
AddressBlock 1090
City
Stock exchangeNASDAQ Capital Market Consolidated
CountrySingapore
Postal code169201
Phone6585127275
Websitehttps://cuprina.com/
Ticker SymbolCUPR
IPO dateApr 10, 2025
CEOMr. Yong Qi (David) Quek
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data